Short Interest in Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) Decreases By 57.8%

Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) was the recipient of a significant decline in short interest in December. As of December 15th, there was short interest totalling 2,700 shares, a decline of 57.8% from the November 30th total of 6,400 shares. Based on an average trading volume of 20,000 shares, the days-to-cover ratio is currently 0.1 days. Approximately 0.0% of the company’s stock are short sold.

Insider Activity at Anebulo Pharmaceuticals

In other Anebulo Pharmaceuticals news, Director Aron R. English bought 10,101,010 shares of the business’s stock in a transaction on Monday, December 23rd. The shares were acquired at an average price of $0.99 per share, with a total value of $9,999,999.90. Following the transaction, the director now owns 15,467,300 shares of the company’s stock, valued at approximately $15,312,627. This trade represents a 188.23 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 85.90% of the stock is currently owned by corporate insiders.

Anebulo Pharmaceuticals Price Performance

Shares of ANEB stock opened at $1.70 on Friday. The company has a market cap of $44.09 million, a P/E ratio of -5.67 and a beta of -1.09. The stock’s 50-day moving average is $1.57 and its 200 day moving average is $1.93. Anebulo Pharmaceuticals has a 1-year low of $0.80 and a 1-year high of $3.30.

Anebulo Pharmaceuticals (NASDAQ:ANEB) last issued its quarterly earnings data on Wednesday, September 25th. The company reported ($0.05) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.08. On average, analysts anticipate that Anebulo Pharmaceuticals will post -0.52 EPS for the current year.

Analyst Ratings Changes

Separately, Benchmark reissued a “speculative buy” rating and issued a $8.00 price objective on shares of Anebulo Pharmaceuticals in a research note on Tuesday, November 19th.

About Anebulo Pharmaceuticals

Anebulo Pharmaceuticals, Inc, a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI.